UNITED-FIRST-PARTNERS
United First Partners ("UFP"), a leading Special Situations Investment & Advisory Group is pleased to announce it has entered into a strategic alliance with the Mariana Group (“Mariana”), a leading Derivatives and Structured Products brokerage group, which is fully FCA regulated and based in London. The combination of UFP and Mariana creates a mid-sized financial services group with a strong reputation in the Equities and Derivatives space. Consequently, Mariana’s regulated entity has been renamed Mariana UFP LLP (FRN 551170) and oversee in excess of 70 professionals in London covering a broad spectrum of value added financial products and services.
This strategic alliance will add to UFP’s current offering in Equities in Europe, as Mariana is a primarily Derivatives and Structured Products brokerage operation, with a strong reputation amongst its peers. UFP and Mariana anticipate significant synergies across business lines in relation to the regulatory challenges expected in the years to come.
UFP and Mariana have upgraded their facilities and entered into new clearing arrangements in order to give Mariana UFP the tools to compete at the highest level.
In the US, UFP LLC (SEC regulated and member of FINRA and SIPC) will continue to operate as a standalone entity, although UFP and Mariana have plans to significantly expand the existing scope of activities in the region, in particular in the Derivatives segment.
Michael Hadjedj, Co-founder of UFP commented: “We are very excited by the strategic alliance we have formed with Mariana. We believe that our industry needs consolidation and Mariana UFP wants to be at the heart of it. UFP’s strong niche research offering combined with Mariana’s cross-asset execution platform and large market share in the derivatives space is a powerful combination to seize opportunities in our industry.”
Daniel Hawkins, Co-founder and CEO of Mariana added, “We are very pleased to join forces with UFP, which brings to Mariana access to a strong research franchise to complement our existing Macro-Economic and Derivative Strategy offering. We are now working towards generating synergies across the group’s business lines, and leveraging on UFP’s presence in the US. We are also preparing actively for the transition to MIFID II in Europe and feel our enlarged group is well positioned.”
About United First Partners
United First Partners (“UFP”) is a global leading Special Situations Investment & Advisory Group, offering a wide range of merchant banking and investment advisory services to institutional and private clients. These services range from sale and purchase of strategic assets to corporate finance, debt and equity capital markets and wealth management.
Our strategy and core values allowed us to build an extensive customer base including leading hedge funds, private equity funds, long-only funds, corporates, sovereign wealth funds and family offices. Our achievements, independence, unique business model and strong reputation have enabled UFP to become an attractive and reliable partner for business associates and talented professionals.
Over the past 6 years, UFP has been recognised as the #1 independent Pan European Special Situations research by industry leading survey Extel.
For further details, please visit www.utdfirst.com
About Mariana Capital
Mariana Capital Markets is a diversified, independent financial services intermediary providing bespoke advisory and strategy services. The firm was founded in 2009 to create and distribute innovative, high performance investment solutions and provide the highest quality service to our clients.
From our headquarters in the City of London, we offer global financial solutions ranging from Market Strategy and Tax Advisory to Structured Products and Estate Planning Solutions.
These services complement our status as a market leading execution venue for Cash Equities, Equity Futures and Options, Commodities, and Fixed Income products.
For further details, please visit www.marianainvestments.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20170509006106/en/
Contact:
Press Enquiries:
Sara Caniggia
+44 207 050 6803
media@utdfirst.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Therapeutics to Present Broad Range of Clinical, Real-World and Mechanistic Data at TOXINS 20268.12.2025 08:00:00 CET | Press release
Merz Therapeutics to present more than 20 abstracts and posters at the TOXINS 2026 8th International Conference, taking place January 14-17 2026 in Madrid, Spain. Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced that the company will present more than 20 clinical and non-clinical abstracts and posters spanning spasticity, movement disorders, and neurotoxin science at the TOXINS 2026 8th International Conference, taking place January 14–17, 2026, in Madrid, Spain. These presentations underscore the company’s commitment to addressing unmet needs in neurological disorders. “Our research reflects a relentless focus on improving patient outcomes through innovation in neurotoxin science,” said Dr. Stefan Albrecht, Chief Scientific and Medical Officer at Merz Therapeutics. “By presenting these new data at TOXINS 2026, we aim to foster scientific exchange and advance treatment strategies that address real-world challenges for patients and clinicians.”
Galderma Welcomes Increased Equity Investment From L’Oréal8.12.2025 07:05:00 CET | Press release
L’Oréal to acquire an additional 10% stake in Galderma recognizing its scientific leadership in dermatology and long-term growth potential Ad hoc announcement pursuant to Art. 53 LR Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced that L’Oréal Groupe intends to increase its equity investment in the company, acquiring an additional 10% stake from Sunshine SwissCo GmbH (a consortium led by EQT, Abu Dhabi Investment Authority (ADIA), and Auba Investment Pte. Ltd., acting as sellers). Following the transaction, which is subject to customary approvals, L’Oréal’s total shareholding in Galderma will rise to 20%, building on its initial investment made in August 2024. The transaction is expected to close in Q1 2026. In connection with this increased investment, Galderma will consider nominating two non-independent board candidates from L’Oréal, replacing the board members representing the consortium led by EQT, at the 2026 Annual General Meeting. Additio
Ant International Wins Champion of NeurIPS Competition of Fairness in AI Face Detection8.12.2025 04:37:00 CET | Press release
The Challenge: Deepfakes undermine both the accuracy and fairness of AI face detection due to variations in human features.The Technology: Ant International’s AI model uses a novel ‘Mixture of Experts’-based Adversarial Debiasing approach to achieve superior fairness and accuracy across diverse demographics.The Impact: This advancement strengthens payment security, offering robust protection against deepfake fraud and enhancing eKYC compliance globally. Ant International, a leading global digital payment, digitisation, and financial technology provider, has won first place at the NeurIPS Competition of Fairness in AI Face Detection. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207210856/en/ Ant International’s solution takes top spot at the NeurIPS Competition of Fairness in AI Face Detection, emerging first among over 2,100 submissions from 162 teams globally. AI Fairness enhances Financial Security Studies by the Nati
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release
Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom